SCHEMBL4471161

SCHEMBL4471161

CC(C)(C)N1CCOCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.37
USP2 O75604 1/20 0.37
MGLL Q99685 1/20 0.36
ALDH1A1 P00352 5/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
CA12 O43570 2/20 0.33
CA7 P43166 1/20 0.33
CA14 Q9ULX7 1/20 0.33
RECQL P46063 1/20 0.32
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
OPRM1 P35372 1/20 0.32
GRIN1 Q05586 1/20 0.32
KCNH2 Q12809 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85406 1.00 SMN1; SMN2 (0.37) SMN1; SMN2USP2MGLLALDH1A1TSHR
SCHEMBL408923 0.97 SMN1; SMN2 (0.40) SMN1; SMN2USP2MGLLALDH1A1TSHR
SCHEMBL409231 0.97 SMN1; SMN2 (0.40) SMN1; SMN2USP2MGLLALDH1A1TSHR
SCHEMBL23084144 0.97 SMN1; SMN2 (0.40) SMN1; SMN2USP2MGLLALDH1A1TSHR
SCHEMBL24590134 0.97 SMN1; SMN2 (0.40) SMN1; SMN2USP2MGLLALDH1A1TSHR
SCHEMBL679559 0.89 PDK1 (0.34) SMN1; SMN2USP2MGLLALDH1A1TSHR
SCHEMBL16219454 0.87 ALDH1A1 (0.38) SMN1; SMN2USP2ALDH1A1TSHRMAPK1
SCHEMBL21919453 0.84 SMN1; SMN2 (0.32) SMN1; SMN2USP2MGLLALDH1A1
SCHEMBL15503287 0.83 MEN1 (0.52) SMN1; SMN2USP2ALDH1A1TSHRMAPK1
SCHEMBL15503301 0.83 MEN1 (0.52) SMN1; SMN2USP2ALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550486-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 US disclosed
US-7351720-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ACKR3, CCR7, CCR2 SMN1; SMN2 4441/4885USP2 1421/4885MGLL 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.